TerminatedPhase 3NCT02785900
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Studying Acute promyelocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Seagen Inc.
- Principal Investigator
- Phoenix Ho, MDSeagen Inc.
- Intervention
- 33A(drug)
- Enrollment
- 240 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2017
Study locations (30)
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- City of Hope National Medical Center, Duarte, California, United States
- Pacific Hematology Oncology Associates, San Francisco, California, United States
- Colorado Blood Cancer Institute, Denver, Colorado, United States
- Florida Cancer Specialists - South Region, Fort Myers, Florida, United States
- Shands Cancer Center / University of Florida, Gainesville, Florida, United States
- Memorial Cancer Institute, Miami, Florida, United States
- Florida Center for Cellular Therapy / Blood and Marrow Transplant Center, Orlando, Florida, United States
- Florida Cancer Specialists - North Region, St. Petersburg, Florida, United States
- Northside Hospital, Atlanta, Georgia, United States
- OnCare Hawaii, Honolulu, Hawaii, United States
- Rush University Medical Center, Chicago, Illinois, United States
- University of Chicago, Chicago, Illinois, United States
- University of Kansas Cancer Center, Westwood, Kansas, United States
- Norton Cancer Institute, Louisville, Kentucky, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02785900 on ClinicalTrials.govOther trials for Acute promyelocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07563179Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaShenzhen University General Hospital
- RECRUITINGPHASE3NCT07504458Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaQuetzal Therapeutics
- RECRUITINGPHASE3NCT07223814Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)Stichting Hemato-Oncologie voor Volwassenen Nederland
- ACTIVE NOT RECRUITINGNANCT07187505Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic LeukemiaAnhui Medical University
- RECRUITINGPHASE3NCT07503730Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).First Affiliated Hospital Xi'an Jiaotong University
- ENROLLING BY INVITATIONNANCT06697327Daunorubicin + Cytarabine + Venetoclax in de Novo AMLAnhui Medical University
- RECRUITINGPHASE1NCT06313437Revumenib in Combination With 7+3 + Midostaurin in AMLRichard Stone, MD
- RECRUITINGPHASE3NCT06578247Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLDaiichi Sankyo